Three French biotechs planning Euronext IPOs

Oncodesign S.A. (Dijon, France), Genomic Vision S.A. (Paris, France) and Genticel S.A. (Labege, France) are all planning IPOs on NYSE Euronext. Oncodesign is aiming to sell 1.5 million shares at EUR 6.42-EUR 7.34. At the EUR 6.88 midpoint, the company would raise EUR 10 million ($13.9 million) and be valued at EUR 40.2 million ($55.9 million). The offering is slated to price on March 27, and Oncodesign is slated to start trading on April 2. CM-CIC Securities; LCM; and Arkeon are managing the offering. Oncodesign is focused on drug discovery work for cancer compounds and has deals with UCB Group (Euronext:UCB); Sanofi (Euronext:SAN; NYSE:SNY); and Ipsen Group (Euronext:IPN). ...